Tumor Necrosis Factor News and Research

RSS

Booster doses of mRNA vaccines improve humoral immunogenicity in patients with inflammatory bowel disease

Researchers evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with inflammatory bowel disease.

30 Dec 2021

Transcription factor Blimp1 identified as potential target for modulating T-reg activity to treat cancer

In cancer, a major obstacle to anti-tumor immunity and immunotherapy treatment is the infiltration of regulatory T cells, or T-reg cells, into a tumor. These immune cells generally turn down the immune response, and they can prevent the immune system from destroying cancer cells.

22 Dec 2021

Impact of acute kidney injury associated gene expression in human kidney cells

A new study attempts to perform a comparative single-cell census of human kidneys employing samples from individuals suffering from acute kidney injury and controls without the condition.

20 Dec 2021

Echinacea purpurea may help prevent respiratory tract infections during COVID-19 pandemic

A new study describes the results of using an extract of the medicinal plant Echinacea purpurea to treat non-severe cases of COVID-19.

19 Dec 2021

A new approach for drugs to be more effective against inflammatory bowel disease

Biomedical scientists at the University of California, Riverside, propose a way for drugs to be more effective against inflammatory bowel disease, or IBD, in which the intestine undergoes inflammation.

18 Dec 2021

Weak T-cell clonal response to SARS-CoV-2 vaccination in IBD patients deficient in antibody-responders

Researchers investigate the post-vaccination clonal T-cell response and its relationship to antibody responses in IBD patients.

15 Dec 2021

New mRNA vaccine platform provides stronger protection against SARS-CoV-2 delta variant

A group of researchers from various institutions developed a nucleoside-modified mRNA vaccine that encodes the SARS-CoV-2 N protein (mRNA-N) and is formulated in lipid nanoparticles for this investigation (LNP).

14 Dec 2021

Bioinformatics pipeline can be used to quickly identify SARS-CoV-2 therapeutics

In a new study, researchers developed a bioinformatics pipeline that uses RNA sequencing data to identify altered genes and signaling pathways affected by viral infection.

13 Dec 2021

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

In a recent study conducted at Yale University, USA, scientists have investigated the immunogenicity of mRNA-based coronavirus disease 2019 (COVID-19) vaccine candidates encoding the spike proteins of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The findings reveal that the vaccines induce robust immune responses against SARS-CoV-2 variants. The study is currently available on the bioRxiv* preprint server.

6 Dec 2021

Acute SARS-CoV-2 infection during pregnancy associated with placental ACE2 shedding

A new study, published on the bioRxiv* preprint server, hypothesized that ACE-2 expression and ADAM17 activity in the placenta is affected by the timing of SARS-CoV-2 infection of the mother.

24 Nov 2021

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

A new study evaluates the efficacy of SNX-5422 as a post-exposure prophylactic treatment.

23 Nov 2021

A trio of proteins found to drive inflammation in psoriasis

About 7.5 million Americans suffer from psoriasis, an autoimmune disease that shows up as patches of red, inflamed skin and painful, scaly rashes. Although there are effective treatments for psoriasis, not everyone responds to these therapies - and for many, the relief is temporary.

21 Nov 2021

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors - a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions - generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis.

21 Nov 2021

NIH study finds naturally acquired immunity is weak against SARS-CoV-2 variants

Immunity acquired after recovering from SARS-CoV-2 infection is not sufficient in protecting against reinfection from variants.

18 Nov 2021

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

A recent study evaluates the immune responses elicited by COVID-19 vaccines in infliximab- or vedolizumab-treated IBD patients.

15 Nov 2021

SARS-CoV-2 infection inhibited by CCR2 signaling

A new study discusses the role of monocytes in protecting individuals from SARS-CoV-2.

15 Nov 2021

COVID-19 vaccination humoral immune response in individuals with diabetes

A new study investigated the humoral immune response and side effects related to COVID-19 vaccines in individuals with type 1 diabetes and type 2 diabetes.

12 Nov 2021

Current understanding of the link between COVID-19 and cardiovascular disease

A review published in Chemo-Biological Interactions has focused on the prevalence of COVID-19 in CVD patients associated with ACE2 mechanisms.

10 Nov 2021

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

Despite clear directives outlined in the updated guidelines published by the American College of Rheumatology/National Psoriasis Foundation (ACR/NPF) in 2018, there is limited data regarding medication use in real-world clinical practice and patient medication preferences for the treatment of psoriatic arthritis (PsA).

9 Nov 2021

Pfizer COVID-19 vaccine elicits durable specific memory T-cell response

A new preprint describes the protective efficacy of memory T-cells developed in response to the viral antigen, which could offer long-term immunity.

4 Nov 2021